1. Use of miRNA Response Sequences to Block Off-target Replication and Increase the Safety of an Unattenuated, Glioblastoma-targeted Oncolytic HSV
- Author
-
Michael A. Caligiuri, Justus B. Cohen, Hiroaki Uchida, Balveen Kaur, Yoshitaka Miyagawa, Joseph C. Glorioso, Timothy P. Cripe, Lucia Mazzacurati, Nduka Amankulor, Bonnie Reinhart, Aofei Li, Paola Grandi, Marco Marzulli, Nino Chiocca, and William F. Goins
- Subjects
Pharmacology ,HEK 293 cells ,Biology ,Virology ,Immediate early protein ,Virus ,Oncolytic virus ,Viral replication ,Lytic cycle ,Drug Discovery ,microRNA ,Genetics ,Molecular Medicine ,Original Article ,Vector (molecular biology) ,Molecular Biology - Abstract
Glioblastoma multiforme (GBM) is an aggressive brain cancer for which there is no effective treatment. Oncolytic HSV vectors (oHSVs) are attenuated lytic viruses that have shown promise in the treatment of human GBM models in animals, but their efficacy in early phase patient trials has been limited. Instead of attenuating the virus with mutations in virulence genes, we engineered four copies of the recognition sequence for miR-124 into the 3′UTR of the essential ICP4 gene to protect healthy tissue against lytic virus replication; miR-124 is expressed in neurons but not in glioblastoma cells. Following intracranial inoculation into nude mice, the miR-124-sensitive vector failed to replicate or show overt signs of pathogenesis. To address the concern that this safety feature may reduce oncolytic activity, we inserted the miR-124 response elements into an unattenuated, human receptor (EGFR/EGFRvIII)-specific HSV vector. We found that miR-124 sensitivity did not cause a loss of treatment efficiency in an orthotopic model of primary human GBM in nude mice. These results demonstrate that engineered miR-124 responsiveness can eliminate off-target replication by unattenuated oHSV without compromising oncolytic activity, thereby providing increased safety.
- Published
- 2015